11 research outputs found
Eesti Haigekassa kliinilise auditi „Hulgimüeloomi diagnoosiga patsientide käsitlus Eesti haiglates“ kokkuvõte
Get PDFEesti Arst 2021; 100(3):137–145
 
Müeloomtõve ravistrateegiate efektiivsus ja kulutõhusus:tervisetehnoloogia hindamise raport TTH07
Get PDFHulgimüeloomi raviskeemide efektiivsus ja kulutõhusus: tervisetehnoloogia hindamise raport TTH27
Get PDFRavimite rahastus Eestis – aeg muutusteks
Get PDFTööealise elanikkonna haigestumine on üks peamisi majanduskasvu peetumise allikaid globaalselt ning Eesti ei ole erand. Olukorra parandamisel on lisaks inimeste tervisekäitumisele ja meditsiinipersonali olemasolule kriitilise tähtsusega tänapäevase ravi kättesaadavus. Euroopas läbiviidud uuringu andmetel on 160 ravimist, mille Euroopa Ravimiamet on viimase 4 aasta jooksul heaks kiitnud, Eestis kättesaadavad vaid 41 ning aeg ravimi soodusravimite nimekirja arvamiseni on Eestis keskmiselt 599 päeva. Sellega jääb Eesti maha Euroopa Liidu keskmisest ja on pingereas tagapool mitmest meist majanduslikult nõrgemast riigist. Praegusele parimale teadmisele tuginedes on olukorra parandamiseks vaja uuendada Eesti tervisetehnoloogiate hindamise süsteemi ja siduda ravimitele soodustuse andmise piirmäärad majanduse arengu tasemega
Tisageenlekleutseel retsidiveerunud või refraktaarse ägeda lümfoblastleukeemia ravis: tervisetehnoloogia hindamise raport TTH60
Get PDFhttps://www.ester.ee/record=b5531333*es
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission : a study from the Acute Leukemia Working Party of the EBMT
No full textPeer reviewe
Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor (ClinTrialGov 00342316)
No full textPre-transplant somatic co-occurring mutations (by next generation sequencing) in acute myeloid leukemia: frequency and impact on clinical outcomes after allogeneic hematopoietic cell transplantation - a large study on behalf of the EBMT Acute Leukemia Working Party [Abstact]
No full textPneumocystis pneumonia after allogeneic hematopoietic cell transplantation:A case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
No full textMyeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study.
No full textAlthough most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2-18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective "real-world-practice" study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial
